AMRN presents REDUCE-IT legacy analysis at ESC 2026
AMRN presented new REDUCE-IT legacy analysis at the European Society of Cardiology (ESC) Congress 2026 on persistent cardiovascular benefit after icosapent ethyl cessation in adherent patients.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.